Autologous stem cell transplant is an effective therapy for carefully selected patients with AL amyloidosis: Experience of a single institution

British Journal of Haematology

Volumn 164, Issue 5, 2014, Pages 722-728

  Jimenez Zepeda, Victor H ^a   Franke, Norman ^a   Reece, Donna E ^a   Trudel, Suzanne ^a   Chen, Christine ^a   Delgado, Diego H ^b   Winter, Andrew ^a   Mikhael, Joseph R ^c   Tiedemann, Rodger ^a   Kukreti, Vishal ^a  

^a PRINCESS MARGARET HOSPITAL   (Canada)

^b UNIVERSITY HEALTH NETWORK   (Canada)

^c MAYO CLINIC   (United States)

Author keywords

Brain natriuretic peptide; High dose melphalan; Light chain amyloidosis; Transplantation; Troponin I

Indexed keywords

BRAIN NATRIURETIC PEPTIDE; HIGH-DOSE MELPHALAN; LIGHT-CHAIN AMYLOIDOSIS; TRANSPLANTATION; TROPONIN I;

ADULT; AGED; AMYLOIDOSIS; BIOLOGICAL MARKERS; FEMALE; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HUMANS; MALE; MIDDLE AGED; NATRIURETIC PEPTIDE, BRAIN; PATIENT SELECTION; RETROSPECTIVE STUDIES; SURVIVAL ANALYSIS; TREATMENT OUTCOME; TROPONIN I;

EID: 84894061446     PISSN: 00071048     EISSN: 13652141     Source Type: Journal    
DOI: 10.1111/bjh.12673     Document Type: Article

References (25)

1. Apridonidze, T., Steingart, R.M., Comenzo, R.L., Hoffman, J., Goldsmith, Y., Bella, J.N., Landau, H. & Liu, J.E. (2012) Clinical and echocardiographic correlates of elevated troponin in amyloid light-chain cardiac amyloidosis. American Journal of Cardiology, 110, 1180-1184.
2. Cibeira, M.T., Sanchorawala, V., Seldin, D.C., Quillen, K., Berk, J.L., Dember, L.M., Segal, A., Ruberg, F., Meier-Ewert, H., Andrea, N.T., Sloan, J.M., Finn, K.T., Doros, G., Blade, J. & Skinner, M. (2011) Outcome of AL amyloidosis after high-dose melphalan and autologous stem cell transplantation: long-term results in a series of 421 patients. Blood, 118, 4346-4352.
3. Cohen, A.D., Zhou, P., Chou, J., Teruya-Feldstein, J., Reich, L., Hassoun, H., Levine, B., Filippa, D.A., Riedel, E., Kewalramani, T., Stubblefield, M.D., Fleisher, M., Nimer, S. & Comenzo, R.L. (2007) Risk-adapted autologous stem cell transplantation with adjuvant dexamethasone +/- thalidomide for systemic light-chain amyloidosis: results of a phase II trial. British Journal of Haematology, 139, 224-233.
4. Comenzo, R.L. (2000) Hematopoietic cell transplantation for primary systemic amyloidosis: what have we learned. Leukaemia & Lymphoma, 37, 245-258.
5. wComenzo, R.L. (2006) Systemic immunoglobulin light-chain amyloidosis. Clin Lymphoma Myeloma, 7, 182-185.
6. Dispenzieri, A., Lacy, M.Q., Kyle, R.A., Therneau, T.M., Larson, D.R., Rajkumar, S.V., Fonseca, R., Greipp, P.R., Witzig, T.E., Lust, J.A. & Gertz, M.A. (2001) Eligibility for hematopoietic stem-cell transplantation for primary systemic amyloidosis is a favorable prognostic factor for survival. Journal of Clinical Oncology, 19, 3350-3356.
7. Dispenzieri, A., Kyle, R.A., Gertz, M.A., Therneau, T.M., Miller, W.L., Chandrasekaran, K., McConnell, J.P., Burritt, M.F. & Jaffe, A.S. (2003) Survival in patients with primary systemic amyloidosis and raised serum cardiac troponins. Lancet, 361, 1787-1789.
8. Dispenzieri, A., Kyle, R.A., Lacy, M.Q., Therneau, T.M., Larson, D.R., Plevak, M.F., Rajkumar, S.V., Fonseca, R., Greipp, P.R., Witzig, T.E., Lust, J.A., Zeldenrust, S.R., Snow, D.S., Hayman, S.R., Litzow, M.R., Gastineau, D.A., Tefferi, A., Inwards, D.J., Micallef, I.N., Ansell, S.M., Porrata, L.F., Elliott, M.A. & Gertz, M.A. (2004) Superior survival in primary systemic amyloidosis patients undergoing peripheral blood stem cell transplantation: a case-control study. Blood, 103, 3960-3963.
9. Gertz, M.A., Lacy, M.Q., Dispenzieri, A. & Hayman, S.R. (2005a) Amyloidosis: diagnosis and management. Clin Lymphoma Myeloma, 6, 208-219.
10. Gertz, M.A., Comenzo, R., Falk, R.H., Fermand, J.P., Hazenberg, B.P., Hawkins, P.N., Merlini, G., Moreau, P., Ronco, P., Sanchorawala, V., Sezer, O., Solomon, A. & Grateau, G. (2005b) Definition of organ involvement and treatment response in immunoglobulin light chain amyloidosis (AL): a consensus opinion from the 10th International Symposium on Amyloid and Amyloidosis, Tours, France, 18-22 April 2004. American Journal of Hematology, 79, 319-328.
11. Gertz, M.A., Lacy, M.Q., Dispenzieri, A., Hayman, S.R., Kumar, S.K., Dingli, D., Ansell, S.M., Gastineau, D.A., Inwards, D.J., Johnston, P.B., Litzow, M.R., Micallef, I.N., Porrata, L.F., Leung, N., Hogan, W.J. & Buadi, F.K. (2010) Autologous stem cell transplant for immunoglobulin light chain amyloidosis: a status report. Leukaemia & Lymphoma, 51, 2181-2187.
12. Gertz, M.A., Lacy, M.Q., Dispenzieri, A., Kumar, S.K., Buadi, F.K., Dingli, D., Leung, N., Hogan, W.J. & Hayman, S.R. (2011) Trends in day 100 and 2-year survival after auto-SCT for AL amyloidosis: outcomes before and after 2006. Bone Marrow Transplantation, 46, 970-975.
13. Iwanaga, Y., Nishi, I., Furuichi, S., Noguchi, T., Sase, K., Kihara, Y., Goto, Y. & Nonogi, H. (2006) B-type natriuretic peptide strongly reflects diastolic wall stress in patients with chronic heart failure: comparison between systolic and diastolic heart failure. Journal of the American College of Cardiology, 47, 742-748.
14. Jaccard, A., Moreau, P., Leblond, V., Leleu, X., Benboubker, L., Hermine, O., Recher, C., Asli, B., Lioure, B., Royer, B., Jardin, F., Bridoux, F., Grosbois, B., Jaubert, J., Piette, J.C., Ronco, P., Quet, F., Cogne, M. & Fermand, J.P. (2007) High-dose melphalan versus melphalan plus dexamethasone for AL amyloidosis. New England Journal of Medicine, 357, 1083-1093.
15. Kumar, S., Dispenzieri, A., Lacy, M.Q., Hayman, S.R., Buadi, F.K., Colby, C., Laumann, K., Zeldenrust, S.R., Leung, N., Dingli, D., Greipp, P.R., Lust, J.A., Russell, S.J., Kyle, R.A., Rajkumar, S.V. & Gertz, M.A. (2012) Revised prognostic staging system for light chain amyloidosis incorporating cardiac biomarkers and serum free light chain measurements. Journal of Clinical Oncology, 30, 989-995.
16. Kyle, R.A., Gertz, M.A., Greipp, P.R., Witzig, T.E., Lust, J.A., Lacy, M.Q. & Therneau, T.M. (1999) Long-term survival (10 years or more) in 30 patients with primary amyloidosis. Blood, 93, 1062-1066.
17. Lebovic, D., Hoffman, J., Levine, B.M., Hassoun, H., Landau, H., Goldsmith, Y., Maurer, M.S., Steingart, R.M., Cohen, A.D. & Comenzo, R.L. (2008) Predictors of survival in patients with systemic light-chain amyloidosis and cardiac involvement initially ineligible for stem cell transplantation and treated with oral melphalan and dexamethasone. British Journal of Haematology, 143, 369-373.
18. Mehta, J., Dispenzieri, A. & Gertz, M.A. (2010) High-dose chemotherapy with autotransplantation in AL amyloidosis: a flawed meta-analysis. Biol Blood Marrow Transplant, 16, 138-140; author reply 140-131.
19. Mhaskar, R., Kumar, A., Behera, M., Kharfan-Dabaja, M.A. & Djulbegovic, B. (2009) Role of high-dose chemotherapy and autologous hematopoietic cell transplantation in primary systemic amyloidosis: a systematic review. Biol Blood Marrow Transplant, 15, 893-902.
20. Palladini, G., Campana, C., Klersy, C., Balduini, A., Vadacca, G., Perfetti, V., Perlini, S., Obici, L., Ascari, E., d'Eril, G.M., Moratti, R. & Merlini, G. (2003) Serum N-terminal pro-brain natriuretic peptide is a sensitive marker of myocardial dysfunction in AL amyloidosis. Circulation, 107, 2440-2445.
21. Palladini, G., Perfetti, V., Obici, L., Caccialanza, R., Semino, A., Adami, F., Cavallero, G., Rustichelli, R., Virga, G. & Merlini, G. (2004) Association of melphalan and high-dose dexamethasone is effective and well tolerated in patients with AL (primary) amyloidosis who are ineligible for stem cell transplantation. Blood, 103, 2936-2938.
22. Palladini, G., Dispenzieri, A., Gertz, M.A., Kumar, S., Wechalekar, A., Hawkins, P.N., Schonland, S., Hegenbart, U., Comenzo, R., Kastritis, E., Dimopoulos, M.A., Jaccard, A., Klersy, C. & Merlini, G. (2012) New criteria for response to treatment in immunoglobulin light chain amyloidosis based on free light chain measurement and cardiac biomarkers: impact on survival outcomes. Journal of Clinical Oncology, 30, 4541-4549.
23. Perfetti, V., Siena, S., Palladini, G., Bregni, M., Di Nicola, M., Obici, L., Magni, M., Brunetti, L., Gianni, A.M. & Merlini, G. (2006) Long-term results of a risk-adapted approach to melphalan conditioning in autologous peripheral blood stem cell transplantation for primary (AL) amyloidosis. Haematologica, 91, 1635-1643.
24. Skinner, M., Anderson, J., Simms, R., Falk, R., Wang, M., Libbey, C., Jones, L.A. & Cohen, A.S. (1996) Treatment of 100 patients with primary amyloidosis: a randomized trial of melphalan, prednisone, and colchicine versus colchicine only. American Journal of Medicine, 100, 290-298.
25. Skinner, M., Sanchorawala, V., Seldin, D.C., Dember, L.M., Falk, R.H., Berk, J.L., Anderson, J.J., O'Hara, C., Finn, K.T., Libbey, C.A., Wiesman, J., Quillen, K., Swan, N. & Wright, D.G. (2004) High-dose melphalan and autologous stem-cell transplantation in patients with AL amyloidosis: an 8-year study. Annals of Internal Medicine, 140, 85-93.